Hyaluronan Inhibitors
10 drugsAbout Hyaluronan
Hyaluronan, or hyaluronic acid (HA), is a glycosaminoglycan distributed throughout the body. It plays roles in tissue hydration, cell migration, and inflammation.
Hyaluronan's involvement in various biological processes makes it a target for drug development. Currently, there is no genetic evidence data available linking hyaluronan to specific diseases.
Hyaluronan is targeted by 11 FDA-approved drugs, including OPDIVO QVANTIG, RITUXAN HYCELA and VYVGART HYTRULO. These drugs are primarily biologics (73%) and antibodies (27%), with applications mainly in oncology.
Strategic Insights
ℹ️ How we calculate- Emerging modalities (Small molecule) signal innovation opportunity.
- phase2 represents biological uncertainty with 59% completion.
Top Hyaluronan Drugs
The competitive landscape includes 5 companies with approved drugs, led by Roche and Bristol-Myers Squibb.
Relatively low number of players suggests moderate barriers to entry, but high competition among incumbents.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| DARZALEX FASPRO | Johnson & Johnson | 2020 | 3 |
| KEYTRUDA QLEX | Merck | 2025 | 2 |
| VYVGART HYTRULO | ARGENX BV | 2023 | 2 |
| PHESGO | Roche | 2020 | 2 |
| RYBREVANT FASPRO | Johnson & Johnson | 2025 | 1 |
| OCREVUS ZUNOVO | Roche | 2024 | 1 |
| HERCEPTIN HYLECTA | Roche | 2019 | 1 |
Hyaluronan Drug Modality Landscape
Modalities
Routes of Administration
Hyaluronan requires biologic approaches (biologic (other)), likely due to its structure or location.
Small molecule approaches may represent a whitespace opportunity to differentiate from existing biologics.
📈 Modality Evolution
Antibodies pioneered Hyaluronan targeting (2017), with enzymes entering more recently (2023).
Hyaluronan Clinical Trials 6,134 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2159 | 825 | 492 | 827 | 63% |
| Phase 2 | 2938 | 972 | 569 | 1374 | 63% |
| Phase 3 | 927 | 361 | 99 | 467 | 78% |
| Phase 4 | 110 | 50 | 13 | 46 | 79% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved Hyaluronan drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Hyaluronan. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Hyaluronan Drug Approval Timeline (2017 - 2025)
The first drug was approved in 2017 (RITUXAN HYCELA), with the most recent in 2026 (RYBREVANT FASPROI).
Recent approvals suggest continued interest, but approaching saturation may increase competition.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 5 companies competing
- • Market share by company
Full Drug Portfolio
- • All 10 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 10-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 5322 clinical trials targeting Hyaluronan.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities